Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Roche/Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS), the first of its kind. According to DRG research and company reports, uptake of the drug for PP-MS has been swift, and the revenue generated has been significant. Nevertheless, opportunity remains because the drug may not be appropriate for all patients. Ocrevus targets neuroinflammation, which may not be present in all PP-MS patients; in addition, according to some KOLs interviewed by DRG, it has only a modest clinical effect. This report examines neurologists’ satisfaction with Ocrevus and the disease-modifying therapies used off-label for PP-MS and gauges the opportunity and value drivers for alternatives to treat this perennially underserved MS subpopulation. With only a handful of therapies in late-stage development that are aimed at halting disability progression in PP-MS—such as MediciNova’s ibudilast—this market is primed for new investment and drug discovery.
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Geographies: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in January 2019
Key drugs covered: Avonex, Aubagio, glatiramer acetate (Copaxone, generics), Gilenya, Ocrevus, Tecfidera, Tysabri
Key metrics included:
Already a Client? Log in to access this report.
Sarah Soucy, is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis. Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her in Animal Science with a Bioscience and Technology option and her in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism